Catalent in deal to buy gene therapy contract manufacturer Paragon for $1.2B
The deal follows by weeks Thermo Fisher's acquisition, for $1.7 billion, of gene therapy contract manufacturing organization Brammer Bio.
Paragon Bioservices raises $13M to expand CRO/CMO work in vaccines, biologics
Paragon Bioservices – a contract research and manufacturing organization, has closed a $13 million round of Series A financing. The Baltimore company’s focused on biologics and vaccine work. The financing was led by NewSpring Capital and Camden Partners. Paragon CEO Marco Chacon described the fundraise as indicative of “an inflection point for the company,” now that […]
Tackling Rising Drug Costs and Growing Popularity of GLP-1’s
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.